Home › Funds › SymBiosis Capital Partners, LLC › EVMN
SymBiosis Capital Partners, LLC position in EVMN
EVOMMUNE INC · Health Care
SymBiosis Capital Partners, LLC reported holding 1,280,778 shares of EVMN (EVOMMUNE INC) in its Q1 2026 13F filing — a position valued at US$29.4M, representing 55.80% of its reported portfolio and ranking #1 among its reported holdings. SymBiosis Capital Partners, LLC has disclosed EVMN holdings in 2 of the last 2 reported quarters, going back to Q4 2025.
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
How SymBiosis Capital Partners, LLC's EVMN position evolved
SymBiosis Capital Partners, LLC first disclosed a stake in EVMN in Q4 2025 at 1,280,778 shares (US$21.9M). The position peaked in Q1 2026 at 1,280,778 shares, worth US$29.4M. Across 2 filings, SymBiosis Capital Partners, LLC held the position steady without any share-count change. The most recent filing (Q1 2026) shows 1,280,778 shares valued at US$29.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.28M | $21.93M | New |
| Q1 2026 | 1.28M | $29.45M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EVMN and 13F data
EVMN (EVOMMUNE INC) is a Health Care company. 116 other funds we track also report a position in EVMN — the largest reported positions include EQT Fund Management S.a r.l. (US$70.3M), RA CAPITAL MANAGEMENT, L.P. (US$46.4M), Pivotal bioVenture Partners Investment Advisor LLC (US$25.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EVMN
- EQT Fund Management S.a r.l. 5.29M sh · $70.28M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 3.49M sh · $46.44M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.93M sh · $25.61M · Q2 2026
- Nan Fung Group Holdings Ltd 1.44M sh · $19.15M · Q2 2026
- Defilade Capital Management, L.P. 793.14K sh · $10.54M · Q2 2026
- Velan Capital Investment Management LP 451.25K sh · $6.00M · Q2 2026
- GREAT POINT PARTNERS LLC 325.00K sh · $4.32M · Q2 2026
- Blue Owl Capital Holdings LP 180.00K sh · $2.39M · Q2 2026
- NEXTBio Capital Management LP 119.06K sh · $1.58M · Q2 2026
- Avidity Partners Management LP 75.00K sh · $996.75K · Q2 2026
- Andera Partners 97.36K sh · $804.21K · Q3 2026
More on SymBiosis Capital Partners, LLC
FAQ
How long has SymBiosis Capital Partners, LLC held EVMN?
SymBiosis Capital Partners, LLC has disclosed EVMN holdings in 2 of the last 2 reported quarters, going back to Q4 2025.
What is SymBiosis Capital Partners, LLC's current position in EVMN?
As of Q1 2026, SymBiosis Capital Partners, LLC holds 1.28M shares of EVMN (EVOMMUNE INC), valued at $29.45M, representing 55.80% of its reported portfolio and ranking #1.
Has SymBiosis Capital Partners, LLC been buying or selling EVMN?
In the latest 13F filing (Q1 2026), SymBiosis Capital Partners, LLC held unchanged its position in EVMN. The position peaked in Q1 2026 at 1.28M shares.
Which other funds hold EVMN?
Other major institutional holders of EVMN include EQT Fund Management S.a r.l., RA CAPITAL MANAGEMENT, L.P., Pivotal bioVenture Partners Investment Advisor LLC, among 116 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.